Ching-Yi Lin

H.C. Wainwright & Co. on Tuesday initiated coverage on Celladon Corp (NASDAQ: CLDN) after impressive clinical trial results for its gene therapy Mydicar. Wainwright rates Celladon as a Buy with a $31 price target. Analyst Ching-Yi Lin wrote, "Thus far, we believe that the clinical trial results...

Analyst Ching-Yi Lin at Jesup & Lamont has initiated coverage of Human Genome Sciences (NASDAQ: HGSI) with Buy rating. The price target for Human Genome Sciences stock has been set at $35. The company is on track for second-quarter submission of its U.S. and European marketing applications....